{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:38:08Z","timestamp":1788043088390,"version":"build-2784847793"},"reference-count":15,"publisher":"American Association for Cancer Research (AACR)","issue":"4","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Summary:<\/jats:title>\n               <jats:p>Despite the remarkable efficacy of targeted therapies and immunotherapies in B-cell acute lymphoblastic leukemia (B-ALL), relapsed and refractory cases remain a major challenge. In this review, we discuss how integrating targeted agents with immunotherapy could help overcome resistance and improve long-term patient outcomes in B-ALL.<\/jats:p>","DOI":"10.1158\/2643-3230.bcd-25-0036","type":"journal-article","created":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T13:31:41Z","timestamp":1745760701000},"page":"293-297","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination Strategies"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4831-4565","authenticated-orcid":false,"given":"Miguel","family":"Quijada-\u00c1lamo","sequence":"first","affiliation":[{"name":"1Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York."},{"name":"2Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York."},{"name":"3Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, New York."},{"name":"4Mindich Child Health & Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York."},{"name":"5Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3360-958X","authenticated-orcid":false,"given":"Grace","family":"Freed","sequence":"additional","affiliation":[{"name":"1Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York."},{"name":"2Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York."},{"name":"3Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, New York."},{"name":"4Mindich Child Health & Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York."},{"name":"5Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0709-2759","authenticated-orcid":false,"given":"Elvin","family":"Wagenblast","sequence":"additional","affiliation":[{"name":"1Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York."},{"name":"2Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York."},{"name":"3Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, New York."},{"name":"4Mindich Child Health & Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York."},{"name":"5Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York."},{"name":"6Division of Pediatric Hematology-Oncology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,4,27]]},"reference":[{"key":"2025100710271269000_bib1","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"2025100710271269000_bib2","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/ajh.27385","article-title":"BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL","volume":"99","author":"Bauer","year":"2024","journal-title":"Am J Hematol"},{"key":"2025100710271269000_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","article-title":"The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy","volume":"10","author":"Vogler","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"2025100710271269000_bib4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41419-024-06864-7","article-title":"Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation","volume":"15","author":"Enzenm\u00fcller","year":"2024","journal-title":"Cell Death Dis"},{"key":"2025100710271269000_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature21076","article-title":"Metabolic gatekeeper function of B-lymphoid transcription factors","volume":"542","author":"Chan","year":"2017","journal-title":"Nature"},{"key":"2025100710271269000_bib6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Gui\u00e8ze","year":"2019","journal-title":"Cancer Cell"},{"key":"2025100710271269000_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2025100710271269000_bib8","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1182\/blood.2023021088","article-title":"The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis","volume":"143","author":"Lenk","year":"2024","journal-title":"Blood"},{"key":"2025100710271269000_bib9","doi-asserted-by":"crossref","first-page":"e175199","DOI":"10.1172\/JCI175199","article-title":"Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency","volume":"134","author":"Aminov","year":"2024","journal-title":"J Clin Invest"},{"key":"2025100710271269000_bib10","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood.2020008544","article-title":"Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL","volume":"137","author":"Kirchhoff","year":"2021","journal-title":"Blood"},{"key":"2025100710271269000_bib11","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1182\/bloodadvances.2022007364","article-title":"Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis","volume":"6","author":"Vogiatzi","year":"2022","journal-title":"Blood Adv"},{"key":"2025100710271269000_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-021-01117-y","article-title":"Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion","volume":"14","author":"Zhang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2025100710271269000_bib13","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41591-022-01765-8","article-title":"Engineered cellular immunotherapies in cancer and beyond","volume":"28","author":"Finck","year":"2022","journal-title":"Nat Med"},{"key":"2025100710271269000_bib14","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1182\/blood.2023022922","article-title":"The present and future of CAR T-cell therapy for adult B-cell ALL","volume":"145","author":"Rampotas","year":"2025","journal-title":"Blood"},{"key":"2025100710271269000_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ccell.2024.11.006","article-title":"EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function","volume":"43","author":"Isshiki","year":"2025","journal-title":"Cancer Cell"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0036\/3597583\/bcd-25-0036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/4\/293\/3625982\/bcd-25-0036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/4\/293\/3625982\/bcd-25-0036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:27:18Z","timestamp":1759847238000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/6\/4\/293\/763150\/Overcoming-B-ALL-Resistance-to-Targeted-and-Immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,27]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,27]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0036","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,27]]}}}